Stanford University engineers have developed a revolutionary injectable hydrogel depot that can release glucagon-like peptide 1 (GLP-1) drugs slowly, lasting up to 4 months in the body with a single injection. This could significantly improve diabetes management by reducing the need for frequent injections and increasing patient adherence. The new drug delivery system has been tested in rats, and human clinical trials are anticipated to begin within 2 years. The technology has potential applications in treating obesity and other diseases as well. The researchers are working on minimizing side effects and injection volumes in humans before proceeding with larger animal studies and human trials.
Source link
What if a Single GLP-1 Shot Could Last for Months?
